Operator of a genomic medicine delivery company intended to bridge the gap between genome technology and current medical practice. The company connects individuals and health care providers to genetic experts, providing a genetic assessment to individuals regarding the benefits of testing and creating a personalized clinical action plan, enabling patients to make informed treatment decisions at low costs and medical practitioners to accelerate disease diagnosis.
Operator of a disruptive technology platform intended for targeting the decisions that are made in the drug development process. The company offers a tool that helps accelerate the process of drug development reduces the cost and time taken to get the medicines to market, allows medicines to be tested using software, removes the need for unnecessary environmental impacts, enabling businesses to predict toxicological effects and viability of new drugs.
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
